Modified vaccine candidate shipped to the US National Institutes of Health (NIH)
News
NHS Commercial Framework provides ‘welcome clarity’, says ABPI
The framework sets out the NHS’ approach to commercial activity in relation branded medicines
Ocugen’s inherited retinal disease gene therapy OCU400 wins orphan status
Orphan designation granted for the treatment of retinitis pigmentosa and Leber Congenital amaurosis
Sanofi partners with SIRION to improve AAV capsids for gene therapy treatments
Sanofi and SIRION will combine their technology platforms to develop next-generation AAV vectors
Parkinson’s UK creates Vivifi Biotech to research ‘promising’ experimental treatment
Biotech company will be dedicated to accelerating development of potential treatment
NHS England to trial at-home HPV testing kits
Over 31,000 women in London to be offered the at-home tests
Amgen looks to expand access to Otezla in the US
Company has submitted a supplemental new drug application for mild-to-moderate plaque psoriasis
UK sees a 20% growth in the number of advanced therapy trials, report finds
Cell and Gene Therapy Catapult report also found a surge in the number of commercially sponsored trials
MHRA approves Seagen’s Tukysa for HER2-positive breast cancer
Drug approved in a combination regimen for advanced breast cancer patients
Sanofi and GSK begin new study of their COVID-19 vaccine
Companies previously delayed vaccine programme in December 2020
Medica establishes joint venture partnership with Integral Diagnostics
Joint venture, MedX, will provide teleradiology reporting services
ONK Therapeutics enters collaboration with blood cancer charity Anthony Nolan
Agreement will aim to accelerate development of next-generation NK cell therapies
NHS to open mental health support hubs dedicated to staff
Services will be offered to staff who have been affected by the COVID-19 pandemic
AZ withdraws Imfinzi indication in the US for advanced bladder cancer
Decision made in consultation with the FDA following disappointing trial results
Avacta gets MHRA green-light to start phase I trial for ‘pro-drug’ chemotherapy
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta’s pre|CISION chemistry
